Alx Oncology Rg

ALX Oncology—clinical‑stage immuno‑oncology—develops CD47 blocker Evorpacept as combo therapy in Phase 2 gastric/GEJ and head‑neck trials, plus partnerships with Jazz, Quantum Leap, MD Anderson, and Sanofi for expanded solid‑tumor indications.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 44
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ALXO	Alx Oncology Rg Cap: 0.1B	EQUITY	NMS	USD	US00166B1052	Active	📈